The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation

被引:26
|
作者
Bardag-Gorce, F [1 ]
Riley, NE [1 ]
Nan, L [1 ]
Montgomery, RO [1 ]
Li, J [1 ]
French, BA [1 ]
Lue, YH [1 ]
French, SW [1 ]
机构
[1] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA
关键词
Mallory bodies; aggresome; proteasome; PS-341; cytokeratin;
D O I
10.1016/j.yexmp.2003.08.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mallory body (MB) experimental induction takes 10 weeks of drug ingestion. Therefore, it is difficult to study the dynamics and mechanisms involved in vivo. Consequently, an in vitro study was done using primary tissue culture of hepatocytes from drug-primed mice livers in which MBs had already formed. The hypothesis to be tested was that MBs are cytokeratin aggresomes, which form when hepatocytes have a defective ubiquitin-proteasome pathway by which turnover of cytokeratin proteins is prevented. To test this hypothesis, primary tissue cultures of the hepatocytes from normal and MB-forming livers were incubated with the proteasome inhibitor PS-341 and then the cytokeratin filaments and the filament connecting proteins, that is, beta-actin, and ZO1, were visualized by immunofluorescence microscopy. PS-341 caused detachment of the cytokeratins from the cell surface plasma membrane. The cytokeratin filaments retracted toward the nucleus and cytokeratin aggresomes formed. In human livers, MBs showed colocalization of cytokeratin-8 (CK-8) with ubiquitin but not with beta-actin or ZO1. Mouse hepatoma cell lines were studied using PS-341 to induce cytokeratin aggresome formation. In these cell lines, the cytokeratin filaments first retracted toward the nucleus then formed cytokeratin-ubiquitin aggresomes polarized at one side of the nucleus. At the same time, the cells became dissociated from each other, however. The results simulated MB formation. MBs differ from cytokeratin aggresomes both morphologically and in ultrastructure. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 50 条
  • [1] Development of the proteasome inhibitor PS-341
    Adams, J
    [J]. ONCOLOGIST, 2002, 7 (01): : 9 - 16
  • [2] The proteasome inhibitor PS-341 in cancer therapy
    Teicher, BA
    Ara, G
    Herbst, R
    Palombella, VJ
    Adams, J
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2638 - 2645
  • [3] PS-341, a proteasome inhibitor for cancer treatment.
    Adams, J
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U665 - U665
  • [4] Current clinical trials for the proteasome inhibitor PS-341
    不详
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (11): : 1589 - +
  • [5] Proteasome inhibitor, PS341, causes aggresome formation and loss of cell cohesion in a mouse hepatoma cell line
    Riley, NE
    French, SW
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 270A - 271A
  • [6] Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucial
    Garfield, D
    [J]. LANCET ONCOLOGY, 2001, 2 (12): : 714 - 714
  • [7] Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
    Adams, J
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) : 493 - 500
  • [8] Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, P
    Schlossman, R
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    [J]. BLOOD, 2003, 101 (04) : 1530 - 1534
  • [9] Investigative cardiovascular study of the proteasome inhibitor PS-341 in the mouse.
    Rottman, J
    Csizmadia, V
    Ozkaynak, E
    Kadambi, V
    Ganley, K
    Cardoza, K
    Juedes, M
    Bouchard, P
    [J]. TOXICOLOGICAL SCIENCES, 2003, 72 : 47 - 47
  • [10] Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
    Yin, D
    Zhou, H
    Kumagai, T
    Liu, GT
    Ong, JM
    Black, KL
    Koeffler, HP
    [J]. ONCOGENE, 2005, 24 (03) : 344 - 354